[go: up one dir, main page]

ES2124261T3 - 4-(1-hidroxi-, 1-aciloxi-, o 1-carbamoiloxi)-5-hidroxi-2(5h)-furanonas 2- y 5-alquil y fenil sustituidas como agentes antiinflamatorios. - Google Patents

4-(1-hidroxi-, 1-aciloxi-, o 1-carbamoiloxi)-5-hidroxi-2(5h)-furanonas 2- y 5-alquil y fenil sustituidas como agentes antiinflamatorios.

Info

Publication number
ES2124261T3
ES2124261T3 ES92911576T ES92911576T ES2124261T3 ES 2124261 T3 ES2124261 T3 ES 2124261T3 ES 92911576 T ES92911576 T ES 92911576T ES 92911576 T ES92911576 T ES 92911576T ES 2124261 T3 ES2124261 T3 ES 2124261T3
Authority
ES
Spain
Prior art keywords
alkyl
phenyl
hidroxi
substituted phenyl
carbons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92911576T
Other languages
English (en)
Inventor
Gary C M Lee
Michael E Garst
George Sachs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2124261T3 publication Critical patent/ES2124261T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60Two oxygen atoms, e.g. succinic anhydride
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)

Abstract

SE DESCRIBEN NUEVOS COMPUESTOS DE FORMULA (I) DE FURANONA ANTIINFLAMATORIA, DONDE R1 ES INDEPENDIENTEMENTE H, FENILO, FENILO ALQUIL C1-C6 SUSTITUIDO, FENILO HALOGENO SUSTITUIDO, O ALQUILO DE 1 A 6 ATOMOS DE CARBONO Y N ES UN ENTERO CON VLORES DE 1 O 2, Y DONDE CUANDO N ES 1 EL GRUPO R1 SE UNE TANTO A LA POSICION 3 COMO A LA 5 DE LA 2-FURANONA, CUANDO N ES 2 R1 SE UNE A AMBAS POSICIONES 3 Y 5, CON LA PREVISION DE QUE CUANDO N ES 1 R1 NO ES H; Y1 ES H, ALQUILO, DE 1 A 20 ATOMOS DE CARBONO, ALQUIL C1-C20 FENILO, ALQUENILO C1-C20 CON UNO O MAS ENLACES OLEFINICOS, PO(OH)2, PO(OH)OR2, PO(OH)R2, PO(OR)2, DONDE R2 ES INDEPENDIENTEMENTE ALQUILO DE 1 A 20 ATOMOS DE CARBONO, FENILO, O FENILO HALOGENO SUSTITUIDO O FENILO ALQUIL C1-C6 SUSTITUIDO, POSTERIORMENTE Y1 ES CO-R3, CO-OR3, SO2R3, CONHR3, SO2NHR3, (CH2)-O-R3 O (CH2)P-O-R3, O (CH2)P-O-(CH2)M-O-R3, DONDE P Y M SON ENTEROS Y SON INDEPENDIENTEMENTE DE 1 A 10 Y R3 ES H, ALQUILO C1-C20, ALQUENILO C1-C20 CON UNO O MAS ENLACES OLEFINICOS, FENILO, FENILOHALOGENO SUSTITUIDO O FENILO ALQUIL C1-C6 SUSTITUIDO CON LA PREVISION DE QUE CUANDO Y1 ES CO-R3, CO-OR3, Y CONHR3, R3 NO ES HIDROGENO; Y2 ES H, ALQUILO DE 1 A 20 ATOMOS DE CARBONO, CO-R4, CO-OR4, CO-NH-R4, PO(OR4)2 O PO(OR4)R4, DONDE R4 ES INDEPENDIENTEMENTE H, ALQUILO DE 1 A 20 ATOMOS DE CARBONO, FENILO O FENILO HALOGENO SUSTITUIDO O FENILO ALQUIL C1-C6 SUSTITUIDO.
ES92911576T 1991-04-30 1992-04-29 4-(1-hidroxi-, 1-aciloxi-, o 1-carbamoiloxi)-5-hidroxi-2(5h)-furanonas 2- y 5-alquil y fenil sustituidas como agentes antiinflamatorios. Expired - Lifetime ES2124261T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/693,204 US5183906A (en) 1991-04-30 1991-04-30 2- and 5-alkyl and phenyl substituted 4-(1-hydroxy, 1-acyloxy or 1-carbamoyloxy)-5-hydroxy-2 (5h)-furanones as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
ES2124261T3 true ES2124261T3 (es) 1999-02-01

Family

ID=24783742

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92911576T Expired - Lifetime ES2124261T3 (es) 1991-04-30 1992-04-29 4-(1-hidroxi-, 1-aciloxi-, o 1-carbamoiloxi)-5-hidroxi-2(5h)-furanonas 2- y 5-alquil y fenil sustituidas como agentes antiinflamatorios.

Country Status (10)

Country Link
US (1) US5183906A (es)
EP (1) EP0579769B1 (es)
JP (1) JP3181054B2 (es)
AT (1) ATE172459T1 (es)
AU (1) AU1923892A (es)
CA (1) CA2109064A1 (es)
DE (1) DE69227366T2 (es)
ES (1) ES2124261T3 (es)
NO (1) NO933918L (es)
WO (1) WO1992019610A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268387A (en) * 1992-04-24 1993-12-07 Allergan, Inc. Pharmaceutical compositions and method for administering 3 and 4-substituted 2(5H)-furanones to a mammal for inhibiting bone loss
AU6556894A (en) * 1993-05-18 1994-12-12 Upjohn Company, The Bisphosphonate esters for treating gastric disorders
JPH09501920A (ja) * 1993-08-19 1997-02-25 ワーナー−ランバート・コンパニー 非ペプチドエンドセリンアンタゴニスト▲i▼
US5464865A (en) * 1993-12-22 1995-11-07 Ortho Pharmaceutical Corporation 4-aryl- and 4-arylthio-5-hydroxy-2(5H)-furanones as inhibitors of phospholipase A2
US5451686A (en) * 1994-04-15 1995-09-19 Allergan, Inc. 3 and 5 alkyl and phenyl 4-(hydroxy or acyloxy)-alkyl substituted 2(5H)-furanones as anti-inflammatory agents
US5639468A (en) * 1995-06-07 1997-06-17 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using manoalide and analogs thereof
US5922759A (en) * 1996-06-21 1999-07-13 Warner-Lambert Company Butenolide endothelin antagonists
AU6603996A (en) * 1995-08-24 1997-03-19 Warner-Lambert Company Furanone endothelin antagonists
US5891892A (en) * 1996-10-29 1999-04-06 Warner-Lambert Company Small molecule biaryl compounds as inhibitors of endothelin converting enzyme
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
EP2583678A3 (en) 2004-06-24 2013-11-13 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
EP3827747A1 (en) 2005-04-28 2021-06-02 Otsuka Pharmaceutical Co., Ltd. Pharma-informatics system
CN101594878A (zh) 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白(rap)-缀合物对肝病症的治疗
DK3395372T3 (da) 2009-02-20 2022-04-19 Enhanx Biopharm Inc System til afgivelse af glutathion-baseret medikament
CN110075069A (zh) 2009-05-06 2019-08-02 实验室护肤股份有限公司 包含活性剂-磷酸钙颗粒复合物的皮肤递送组合物及其应用
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
FR2978963A1 (fr) 2011-08-11 2013-02-15 Ascorbix Nouveaux derives des furanones et composition pharmaceutique les contenant

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2359208A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha,beta-gamma-butyrolactones and beta-substituted-beta-hydroxy-gamma-butyrolactones and the methods of preparing them
US2359096A (en) * 1941-03-21 1944-09-26 Lilly Co Eli beta-substituted-delta alpha, beta-gamma-butyrolactones and beta-substituted - beta - hydroxy-gamma-butyrolactones and methods of preparing them
US4447445A (en) * 1983-08-03 1984-05-08 The Regents Of The University Of Calif. Manoalide, an anti-inflammatory analgesic marine natural product
DE3472958D1 (en) * 1983-08-03 1988-09-01 Univ California Synthetic analgesic and/or anti-inflammatory derivatives of manoalide
US4789749A (en) * 1984-06-18 1988-12-06 The Regents Of The University Of California Manoalide analogs
ZA864674B (en) * 1985-07-01 1988-02-24 Lilly Co Eli Furanone derivatives
US4874782A (en) * 1985-07-01 1989-10-17 Eli Lilly And Company Furanone derivatives
US4786651A (en) * 1986-02-03 1988-11-22 Allergan, Inc. Treatment of cutaneous hyperproliferative dermatoses with manoalide
DE3615157A1 (de) * 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe
US5089485A (en) * 1988-11-18 1992-02-18 Allergan, Inc. Anti-inflammatory furanones
US5037811A (en) * 1990-04-17 1991-08-06 Allergan, Inc. 4-(oxygen, sulfur or nitrogen substituted)-methyl 5-hydroxy-2(5H)-furanones as anti-inflammatory agents
US5043457A (en) * 1990-04-17 1991-08-27 Allergan, Inc. 2(5H)-furanones substituted in the 3 position, as Ca2+ channel antagonists and anti-inflammatory agents
US5059611A (en) * 1988-11-18 1991-10-22 Allergan, Inc. Anti-inflammatory 5-hydroxy-2-furanones
CA1329390C (en) * 1987-06-08 1994-05-10 John N. Bonfiglio Anti-inflammatory furanones
US4916241A (en) * 1988-06-06 1990-04-10 American Home Products Corporation Inhibition of bone loss by 4-substituted-5-hydroxy-2(5H)-furanones
JPH0222271A (ja) * 1988-07-11 1990-01-25 Kuraray Co Ltd 共役γ−オキシブテノライド化合物およびこれを有効成分とする抗潰瘍剤
US4935530A (en) * 1988-10-18 1990-06-19 Allergan, Inc. Process for preparing 5-substituted-3-furaldehydes
EP0369813A3 (en) * 1988-11-18 1991-02-27 Allergan, Inc Anti-inflammatory furanones
US5045564A (en) * 1988-12-07 1991-09-03 Allergan, Inc. Anti-inflammatory 2-furanones
JPH0356472A (ja) * 1988-12-07 1991-03-12 Allergan Inc 抗炎症5―ヒドロキシ―2―フラノンおよびその用途
US5013850A (en) * 1990-03-30 1991-05-07 Allergan, Inc. 4-ethyl and 4-ethenyl-5-hydroxy-2(5H)-furanones substituted on alpha carbon of the ethyl or ethenyl side chain with a long chain alkyl group and on the beta carbon with a polar group, as anti-inflammatory agents

Also Published As

Publication number Publication date
NO933918D0 (no) 1993-10-29
AU1923892A (en) 1992-12-21
EP0579769B1 (en) 1998-10-21
JPH06507171A (ja) 1994-08-11
DE69227366D1 (de) 1998-11-26
EP0579769A1 (en) 1994-01-26
DE69227366T2 (de) 1999-06-10
NO933918L (no) 1993-12-28
JP3181054B2 (ja) 2001-07-03
ATE172459T1 (de) 1998-11-15
US5183906A (en) 1993-02-02
WO1992019610A1 (en) 1992-11-12
CA2109064A1 (en) 1992-10-31

Similar Documents

Publication Publication Date Title
ES2124261T3 (es) 4-(1-hidroxi-, 1-aciloxi-, o 1-carbamoiloxi)-5-hidroxi-2(5h)-furanonas 2- y 5-alquil y fenil sustituidas como agentes antiinflamatorios.
ES527954A1 (es) Un procedimiento para preparar isoxazoles
EG16150A (en) Substituted 1 - hydroxyethyl - triazoly derivatives
BR8707408A (pt) Novos 5-alcoxi-2,4-diamino-alquibenzenos e composicoes de tingimento de cabelo com 5-alcoxi-2,4-diamino-alquil-benzenos
IE830785L (en) Pharmaceutical compositions containing oxicam derivatives
ATE165972T1 (de) 2(5h)- in position 3-substituierte furanone als ca 2+ antagonisten und entzündungshemmende mittel
SE7507254L (sv) Kompositioner i fast form for tvettning, rengoring och blekning, sett att framstella desamma och deras anvendning.
SE7602122L (sv) Nya piperazinyliminorifamyciner och sett att framstella desamma
SE7706392L (sv) N-fosfonometylenmonoaminoalkanmono- och -polyfosfonsyror respektive n-fosfonometylendiaminoalkanpolyfosfonsyror samt sett for deras framstellning
ATE3279T1 (de) Hydroxyneopentyl-hydroxypivalate-bis-halbesters enthaltende zusammensetzungen und verwendung der zusammensetzungen.
EP0368933A4 (en) COMPOSITIONS COMPRISING AZACYCLOALCANES SUBSTITUTED BY 1-OXO-HYDROCARBYL OR THIOHYDROCARBYL.
SE8503415D0 (sv) Novel isoindolinyl-alkyl-piperazines
DE69203551D1 (de) Biologisch abbaubarer Copolyester von 4-Hydroxyprolin und diesen enthaltende pharmazeutische Zusammensetzung.
ES8200648A2 (es) Procedimiento de preparacion de compuestos opacificantes para radiografia y similares
DE3172309D1 (en) Substituted 3,5-diamino-1,2,4-oxadiazoles and 3,5-diamino-1,2,4-thiadiazoles, their preparation and pharmaceutical compositions containing them
DK61785D0 (da) 2-alkoxyaminosulfonylbenzensulfonylurinstofderivater, deres fremstilling og anvendelse som herbicider
ES467861A1 (es) Procedimiento de preparacion de espiro-oxazolidinas esteroi-des y sus esteroisomeros.
SE8004622L (sv) Acylaminobensoesyraderivat
DE3369324D1 (en) Thiolphosphoric-acid esters, their preparation and use
JPS53127450A (en) 3-alkoxy-4-homoisotwistanes, their preparation and perfume compositions containing the same
JPS56142228A (en) Manufacture of chlorophenols
ATE7921T1 (de) Neue kortikoid-17-thioacetale, ihre herstellung und verwendung.
ES8107202A1 (es) Procedimiento para preparar nuevos derivados de oxadiazolin-1,3,4-ona-5.
ES477519A1 (es) Un metodo para producir derivados de bis-trialcohilestanni- lo.
GB2022583A (en) New ionic polyiodo benzene derivatives useful as X-ray contrast media

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 579769

Country of ref document: ES